CSIMarket
 


Syros Pharmaceuticals Inc   (SYRS)
Other Ticker:  
 

Syros Pharmaceuticals Inc 's Tangible Leverage Ratio

SYRS's quarterly Tangible Leverage Ratio and Total Liabilities, Tangible Equity growth


In Spite of the repayements of liabilities of -2.17%, in III Quarter 2023 ,Tangible Leverage Ratio deteriorated to 1.87 is above the company's typical Tangible Leverage Ratio.

Within Major Pharmaceutical Preparations industry in the third quarter 2023, 314 other companies have achieved lower Tangible Leverage Ratio than Syros Pharmaceuticals Inc in the III Quarter 2023. While Tangible Leverage Ratio total ranking has deteriorated compared to the second quarter 2023 from 1045 to 2167 .

Explain Tangible Leverage Ratio?
What is SYRS Market Share?
What are SYRS´s Total Liabilities?


SYRS Tangible Leverage Ratio (Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
Y / Y Tangible Equity Change -71.9 % 136.11 % 70.15 % 49.89 % 21.79 %
Y / Y Total Liabilities Change -14.11 % -27.21 % -29.85 % -26.9 % -22.6 %
Tangible Leverage Ratio MRQ 1.87 0.95 0.59 0.56 0.61
SYRS's Total Ranking # 2167 # 1045 # 1132 # 926 # 1313
Seq. Tangible Equity Change -50.43 % -31.39 % -16.43 % -1.11 % 316.43 %
Seq. Total Liabilities Change -2.17 % 10.59 % -12.26 % -9.52 % -17.09 %



Tangible Leverage Ratio third quarter 2023 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 315
Healthcare Sector # 647
Overall Market # 2167


Tangible Leverage Ratio Statistics
High Average Low
3.07 0.79 0.03
(Jun 30 2022)   (Jun 30 2017)




Financial Statements
Syros Pharmaceuticals Inc 's Tangible Equity $ 36 Millions Visit SYRS's Balance sheet
Syros Pharmaceuticals Inc 's Total Liabilities $ 68 Millions Visit SYRS's Balance sheet
Source of SYRS's Sales Visit SYRS's Sales by Geography


Cumulative Syros Pharmaceuticals Inc 's Tangible Leverage Ratio

SYRS's Tangible Leverage Ratio for the trailling 12 Months

SYRS Tangible Leverage Ratio

(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
Y / Y Tangible Equity TTM Growth -71.9 % 136.11 % 70.15 % 49.89 % 21.79 %
Y / Y Total Liabilities TTM Growth -14.11 % -27.21 % -29.85 % -26.9 % -22.6 %
Tangible Leverage Ratio TTM 0.79 0.65 0.78 0.96 1.17
Total Ranking TTM # 2509 # 1721 # 8 # 1272 # 13
Seq. Tangible Equity TTM Growth -50.43 % -31.39 % -16.43 % -1.11 % 316.43 %
Seq. Total Liabilities TTM Growth -2.17 % 10.59 % -12.26 % -9.52 % -17.09 %


On the trailing twelve months basis Despite of the repayements of liabilities of -2.17% in the trailing twelve months ending in III Quarter 2023, Tangible Leverage Ratio improved to 0.79, below Syros Pharmaceuticals Inc 's average Tangible Leverage Ratio.
Tangible Leverage Ratio is the average cumulative value over the last four quarters.

Among companies in the Major Pharmaceutical Preparations industry 348, during the past 12 months, other companies have achieved lower Tangible Leverage Ratio than Syros Pharmaceuticals Inc . While Tangible Leverage Ratio total ranking has deteriorated during the twelve months ending in the III Quarter 2023, compared to the prior period, from 1721 to 2509.

Explain Tangible Leverage Ratio?
What is SYRS Market Share?
What are SYRS´s Total Liabilities?

TTM Tangible Leverage Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 349
Healthcare Sector # 715
Within the Market # 2509


trailing twelve months Tangible Leverage Ratio Statistics
High Average Low
1.42 0.81 0.13
(Sep 30 2022)   (Dec 31 2017)




Companies with similar Tangible Leverage Ratio in the quarter ending Sep 30 2023, within Major Pharmaceutical Preparations Industry Tangible Leverage RatioSep 30 2023 MRQ Total LiabilitiesSep 30 2023 MRQ Tangible Equity
Clearmind Medicine Inc   5.05 $ 4.970  Millions$ 0.983  Millions
Unicycive Therapeutics Inc   4.72 $ 16.008  Millions$ 3.390  Millions
Intercept Pharmaceuticals inc   4.47 $ 321.317  Millions$ 71.845  Millions
Durect Corp  4.46 $ 36.752  Millions$ 8.237  Millions
Blueprint Medicines Corporation  4.46 $ 902.688  Millions$ 202.611  Millions
Kala Bio inc   4.45 $ 49.897  Millions$ 11.223  Millions
Mustang Bio inc   4.13 $ 16.558  Millions$ 4.009  Millions
Pacira Biosciences inc   4.12 $ 702.911  Millions$ 170.728  Millions
Mersana Therapeutics Inc   4.04 $ 210.709  Millions$ 52.195  Millions
Biolinerx Ltd   3.83 $ 50.702  Millions$ 13.223  Millions
Phibro Animal Health Corporation  3.70 $ 620.465  Millions$ 167.634  Millions
Uniqure N v   3.21 $ 594.878  Millions$ 185.535  Millions
Rockwell Medical inc   3.20 $ 31.088  Millions$ 9.700  Millions
Travere Therapeutics Inc   3.20 $ 553.084  Millions$ 172.863  Millions
Ibio inc   3.13 $ 24.469  Millions$ 7.826  Millions
Perrigo Company Plc  3.07 $ 5,514.500  Millions$ 1,796.700  Millions
Sarepta Therapeutics Inc   3.04 $ 2,322.856  Millions$ 764.357  Millions
Veru Inc   3.01 $ 32.813  Millions$ 10.898  Millions
Flora Growth Corp   2.90 $ 22.365  Millions$ 7.700  Millions
Lucy Scientific Discovery Inc   2.88 $ 3.564  Millions$ 1.237  Millions
Kineta Inc   2.77 $ 7.991  Millions$ 2.889  Millions
Oncotelic Therapeutics Inc   2.73 $ 16.648  Millions$ 6.097  Millions
Marinus Pharmaceuticals Inc   2.65 $ 144.368  Millions$ 54.537  Millions
Ani Pharmaceuticals Inc  2.53 $ 460.053  Millions$ 181.812  Millions
Apellis Pharmaceuticals Inc   2.52 $ 585.945  Millions$ 232.271  Millions
Biovie Inc   2.45 $ 16.212  Millions$ 6.622  Millions
Cryoport inc   2.37 $ 463.128  Millions$ 195.612  Millions
Proqr Therapeutics N v   2.33 $ 108.072  Millions$ 46.357  Millions
Gossamer Bio Inc   2.33 $ 243.308  Millions$ 104.617  Millions
Casi Pharmaceuticals inc   2.29 $ 51.103  Millions$ 22.326  Millions

Date modified: 2023-11-16T19:22:29+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com